| Literature DB >> 31063106 |
B Oporto1, M Ocejo1, M Alkorta2, J M Marimón2, M Montes2, A Hurtado1.
Abstract
In 2014-2016, we conducted a cross-sectional survey in 115 sheep, 104 beef and 82 dairy cattle herds to estimate Shiga toxin-producing Escherichia coli (STEC) prevalence, and collected data on human clinical cases of infection. Isolates were characterised (stx1, stx2, eae, ehxA) and serogroups O157 and O111 identified by PCR, and their antimicrobial resistance (AMR) profiles were determined by broth microdilution. STEC were more frequently isolated from beef cattle herds (63.5%) and sheep flocks (56.5%) than from dairy cattle herds (30.5%) (P < 0.001). A similar but non-significant trend was observed for O157:H7 STEC. In humans, mean annual incidence rate was 1.7 cases/100 000 inhabitants for O157 STEC and 4.7 for non-O157 STEC, but cases concentrated among younger patients. Distribution of virulence genes in STEC strains from ruminants differed from those from human clinical cases. Thus, stx2 was significantly associated with animal STEC isolates (O157 and non-O157), ehxA to ruminant O157 STEC (P = 0.004) and eae to human non-O157 STEC isolates (P < 0.001). Resistance was detected in 21.9% of human and 5.2% of animal O157 STEC isolates, whereas all non-O157 isolates were fully susceptible. In conclusion, STEC were widespread in ruminants, but only some carried virulence genes associated with severe disease in humans; AMR in ruminants was low but profiles were similar to those found in human isolates.Entities:
Keywords: Antimicrobial resistance (AMR); Shiga toxin-producing Escherichia coli (STEC); cattle; haemolytic uremic syndrome (HUS); sheep
Mesh:
Substances:
Year: 2019 PMID: 31063106 PMCID: PMC6518511 DOI: 10.1017/S0950268819000566
Source DB: PubMed Journal: Epidemiol Infect ISSN: 0950-2688 Impact factor: 2.451
Herds/flocks positive to Shiga toxin-producing Escherichia coli (STEC) (any serotype), O157:H7 STEC and non-O157 STEC
| Animal source | Analysed herds | STEC | O157:H7 STEC | Non-O157 STEC | |||
|---|---|---|---|---|---|---|---|
| % (CI) | % (CI) | % (CI) | |||||
| Beef cattle | 104 | 66 | 63.5 (54.5–72.5) | 19 | 18.3 (11.0–25.6) | 61 | 58.7 (49.5–67.9) |
| Dairy cattle | 82 | 25 | 30.5 (21.5–39.5) | 12 | 14.6 (7.7–21.5) | 16 | 19.5 (11.8–27.2) |
| Sheep | 115 | 65 | 56.5 (48.4–64.6) | 23 | 20.0 (13.5–26.5) | 53 | 46.1 (38.0–54.2) |
Combination of virulence genes among Shiga toxin-producing Escherichia coli from ruminants (307 isolates from 156 herds) and human clinical cases (124 isolates)
| O157:H7 | Non-O157 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gene pattern | Total | Beef cattle | Dairy cattle | Sheep | Human | Beef cattle | Dairy cattle | Sheep | Human |
| ( | ( | ( | ( | ( | ( | ( | ( | ||
| 37 (8.6) | 11 | 1 | 19 | 6 | |||||
| 22 (5.1) | 11 | 11 | |||||||
| 6 (1.4) | 2 | 4 | |||||||
| 22 (5.1) | 2 | 2 | 18 | ||||||
| 57 (13.2) | 37 | 3 | 9 | 8 | |||||
| 48 (11.1) | 30 | 9 | 2 | 7 | |||||
| 11 (2.6) | 1 | 2 | 1 | 2 | 1 | 2 | 2 | ||
| 65 (15.1) | 18 | 13 | 19 | 9 | 2 | 2 | 2 | ||
| 19 (4.4) | 4 | 7 | 8 | ||||||
| 98 (22.7) | 27 | 1 | 56 | 14 | |||||
| 10 (2.3) | 8 | 2 | |||||||
| 36 (8.4) | 3 | 2 | 2 | 15 | 1 | 4 | 9 | ||
Fig. 1.Distribution of virulence genes among Shiga toxin-producing Escherichia coli from ruminants (307 isolates from 156 herds) and human clinical cases (124 isolates). (A) Shiga-toxin genes; (B) eae and ehxA genes. Number of isolates is indicated within the columns.
Fig. 2.Annual incidence of confirmed STEC (O157 and non-O157) human infections by age.
Resistance (percentage) and distribution of MICs for the 106 ruminant STEC and 36 human STEC (O111/O157) isolates
White fields denote range of dilutions tested for each antimicrobial agent. MICs equal to or above the range are given as the concentration closest to the range and indicated in bold. MICs equal to or lower than the lowest concentration tested are given as the lowest tested concentration. Vertical lines indicate cut-off values: EUCAST epidemiological cut-offs (for ruminant isolates) are represented by thicker lines; CLSI clinical cut-offs (for human isolates) in thin lines, dashed for intermediate and continued for resistant.
aNo cut-off value given by EUCAST; reference as indicated by double vertical lines were used.
bTrimethoprim/sulfamethoxazole cut-off values are expressed as trimethoprim concentration (range 1:19–16:304).
cAll resistant isolates belonged to serotype O157:H7.
dIntermediate resistance.
Resistance phenotypes of STEC isolates
| Resistance profile | Source ( |
|---|---|
| AMP | Human (1) |
| SXT | Human (2) |
| AMP/SXT | Human (2) |
| AMP/SXT/TET | Sheep (2); dairy cattle (1) |
| AMP/SXT/NAL | Human (1) |
| AMP/GEN/NAL/SXT/(AMC/TBM | Human (1) |
AMP, ampicillin; AMC, amoxicillin/clavulanic acid; GEN, gentamicin; NAL, nalidixic acid; SXT, sulfamethoxazole/trimethoprim (tested separately in animal isolates); TBM, tobramycin; TET, tetracycline.
Intermediate resistance to AMC and TBM.